{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:49:48Z","timestamp":1793317788147,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA046592"],"award-info":[{"award-number":["P30CA046592"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA046592"],"award-info":[{"award-number":["P30CA046592"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Chem Biol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1038\/s41589-022-01248-4","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T12:04:52Z","timestamp":1675339492000},"page":"703-711","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":68,"title":["A selective small-molecule STAT5 PROTAC degrader capable of achieving tumor regression in vivo"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5956-3009","authenticated-orcid":false,"given":"Atsunori","family":"Kaneshige","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longchuan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"McEachern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Meagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renqi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoda","family":"Metwally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Kirchhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2718-9811","authenticated-orcid":false,"given":"Hui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4509-9561","authenticated-orcid":false,"given":"Meilin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8337-220X","authenticated-orcid":false,"given":"Bo","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6406-2126","authenticated-orcid":false,"given":"Duxin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4192-8900","authenticated-orcid":false,"given":"Jeanne A.","family":"Stuckey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaomeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"key":"1248_CR1","first-page":"e27159","volume":"2","author":"Z Wang","year":"2013","unstructured":"Wang, Z. & Bunting, K. D. STAT5 in hematopoietic stem cell biology and transplantation. JAKSTAT 2, e27159 (2013).","journal-title":"JAKSTAT"},{"key":"1248_CR2","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1038\/onc.2012.347","volume":"32","author":"W Vainchenker","year":"2013","unstructured":"Vainchenker, W. & Constantinescu, S. N. JAK\/STAT signaling in hematological malignancies. Oncogene 32, 2601\u20132613 (2013).","journal-title":"Oncogene"},{"key":"1248_CR3","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1089\/jir.2015.0054","volume":"36","author":"A Rani","year":"2016","unstructured":"Rani, A. & Murphy, J. J. STAT5 in cancer and immunity. J. Interferon Cytokine Res. 36, 226\u2013237 (2016).","journal-title":"J. Interferon Cytokine Res."},{"key":"1248_CR4","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1182\/blood-2011-12-397554","volume":"119","author":"C Walz","year":"2012","unstructured":"Walz, C. et al. Essential role for Stat5a\/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2V617F in mice. Blood 119, 3550\u20133560 (2012).","journal-title":"Blood"},{"key":"1248_CR5","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1182\/blood-2011-03-345215","volume":"119","author":"D Yan","year":"2012","unstructured":"Yan, D., Hutchison, R. E. & Mohi, G. Critical requirement for Stat5 in a mouse model of polycythemia vera. Blood 119, 3539\u20133549 (2012).","journal-title":"Blood"},{"key":"1248_CR6","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ajh.25792","volume":"95","author":"E Jabbour","year":"2020","unstructured":"Jabbour, E. & Kantarjian, H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am. J. Hematol. 95, 691\u2013709 (2020).","journal-title":"Am. J. Hematol."},{"key":"1248_CR7","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1084\/jem.189.8.1229","volume":"189","author":"M Nieborowska-Skorska","year":"1999","unstructured":"Nieborowska-Skorska, M. et al. Signal transducer and activator of transcription (STAT)5 activation by BCR\/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR\/ABL and is required for leukemogenesis. J. Exp. Med. 189, 1229\u20131242 (1999).","journal-title":"J. Exp. Med."},{"key":"1248_CR8","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1084\/jem.183.3.811","volume":"183","author":"N Carlesso","year":"1996","unstructured":"Carlesso, N., Frank, D. A. & Griffin, J. D. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr\/Abl. J. Exp. Med. 183, 811\u2013820 (1996).","journal-title":"J. Exp. Med."},{"key":"1248_CR9","doi-asserted-by":"crossref","unstructured":"Ilaria, R. L. Jr & Van, R. A. Etten, P210 and P190BCR\/ABL induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members. J. Biol. Chem. 271, 31704\u201331710 (1996).","DOI":"10.1074\/jbc.271.49.31704"},{"key":"1248_CR10","first-page":"247","volume":"13","author":"K Shuai","year":"1996","unstructured":"Shuai, K. et al. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 13, 247\u2013254 (1996).","journal-title":"Oncogene"},{"key":"1248_CR11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/emmm.201000062","volume":"2","author":"A Hoelbl","year":"2010","unstructured":"Hoelbl, A. et al. Stat5 is indispensable for the maintenance of bcr\/abl-positive leukaemia. EMBO Mol. Med. 2, 98\u2013110 (2010).","journal-title":"EMBO Mol. Med."},{"key":"1248_CR12","doi-asserted-by":"publisher","first-page":"4917","DOI":"10.1182\/blood-2005-10-4110","volume":"107","author":"D Ye","year":"2006","unstructured":"Ye, D. et al. STAT5 signaling is required for the efficient induction and maintenance of CML in mice. Blood 107, 4917\u20134925 (2006).","journal-title":"Blood"},{"key":"1248_CR13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nchembio.775","volume":"8","author":"O Hantschel","year":"2012","unstructured":"Hantschel, O. et al. BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat. Chem. Biol. 8, 285\u2013293 (2012).","journal-title":"Nat. Chem. Biol."},{"key":"1248_CR14","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1182\/blood-2013-02-485573","volume":"122","author":"W Warsch","year":"2013","unstructured":"Warsch, W., Walz, C. & Sexl, V. JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia. Blood 122, 2167\u20132175 (2013).","journal-title":"Blood"},{"key":"1248_CR15","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1182\/blood-2008-12-196055","volume":"114","author":"G Yoshimoto","year":"2009","unstructured":"Yoshimoto, G. et al. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood 114, 5034\u20135043 (2009).","journal-title":"Blood"},{"key":"1248_CR16","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/s41375-017-0005-9","volume":"32","author":"B Wingelhofer","year":"2018","unstructured":"Wingelhofer, B. et al. Pharmacologic inhibition of STAT5 in acute myeloid leukemia. Leukemia 32, 1135\u20131146 (2018).","journal-title":"Leukemia"},{"key":"1248_CR17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3324\/haematol.2019.216986","volume":"105","author":"B Maurer","year":"2020","unstructured":"Maurer, B. et al. High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. Haematologica 105, 435\u2013447 (2020).","journal-title":"Haematologica"},{"key":"1248_CR18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/sj.leu.2402740","volume":"17","author":"H Quentmeier","year":"2003","unstructured":"Quentmeier, H. et al. FLT3 mutations in acute myeloid leukemia cell lines. Leukemia 17, 120\u2013124 (2003).","journal-title":"Leukemia"},{"key":"1248_CR19","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.3390\/cancers11121930","volume":"11","author":"A Orlova","year":"2019","unstructured":"Orlova, A. et al. Direct targeting options for STAT3 and STAT5 in cancer. Cancers (Basel) 11, 1930 (2019).","journal-title":"Cancers (Basel)"},{"key":"1248_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrd.2016.211","volume":"16","author":"AC Lai","year":"2017","unstructured":"Lai, A. C. & Crews, C. M. Induced protein degradation: an emerging drug discovery paradigm. Nat. Rev. Drug Discov. 16, 101\u2013114 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1248_CR21","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","volume":"36","author":"L Bai","year":"2019","unstructured":"Bai, L. et al. A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo. Cancer Cell 36, 498\u2013511 (2019).","journal-title":"Cancer Cell"},{"key":"1248_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/28101","volume":"394","author":"S Becker","year":"1998","unstructured":"Becker, S., Groner, B. & Muller, C. W. Three-dimensional structure of the Stat3\u03b2 homodimer bound to DNA. Nature 394, 145\u2013151 (1998).","journal-title":"Nature"},{"key":"1248_CR23","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S0092-8674(00)81443-9","volume":"93","author":"X Chen","year":"1998","unstructured":"Chen, X. et al. Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell 93, 827\u2013839 (1998).","journal-title":"Cell"},{"key":"1248_CR24","doi-asserted-by":"crossref","unstructured":"Levy, D. E. & Darnell, J. E. Jr STATs: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 3, 651\u2013662 (2002).","DOI":"10.1038\/nrm909"},{"key":"1248_CR25","doi-asserted-by":"publisher","first-page":"8970","DOI":"10.1021\/acs.jmedchem.5b01321","volume":"58","author":"PK Mandal","year":"2015","unstructured":"Mandal, P. K. et al. Targeting the Src homology 2 (SH2) domain of signal transducer and activator of transcription 6 (STAT6) with cell-permeable, phosphatase-stable phosphopeptide mimics potently inhibits Tyr641 phosphorylation and transcriptional activity. J. Med. Chem. 58, 8970\u20138984 (2015).","journal-title":"J. Med. Chem."},{"key":"1248_CR26","doi-asserted-by":"publisher","first-page":"10026","DOI":"10.1074\/jbc.RA117.000567","volume":"293","author":"JM Knight","year":"2018","unstructured":"Knight, J. M. et al. Small molecule targeting of the STAT5\/6 Src homology 2 (SH2) domains to inhibit allergic airway disease. J. Biol. Chem. 293, 10026\u201310040 (2018).","journal-title":"J. Biol. Chem."},{"key":"1248_CR27","unstructured":"Wang, S. et al. Small molecule degraders of stat3. WO2020198435 (2020)."},{"key":"1248_CR28","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1021\/acsmedchemlett.1c00155","volume":"12","author":"H Zhou","year":"2021","unstructured":"Zhou, H. et al. SD-91 as a potent and selective STAT3 degrader capable of achieving complete and long-lasting tumor regression. ACS Med. Chem. Lett. 12, 996\u20131004 (2021).","journal-title":"ACS Med. Chem. Lett."},{"key":"1248_CR29","doi-asserted-by":"publisher","first-page":"11280","DOI":"10.1021\/acs.jmedchem.9b01530","volume":"62","author":"H Zhou","year":"2019","unstructured":"Zhou, H. et al. Structure-based discovery of SD-36 as a potent, selective, and efficacious PROTAC degrader of STAT3 protein. J. Med. Chem. 62, 11280\u201311300 (2019).","journal-title":"J. Med. Chem."},{"key":"1248_CR30","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1182\/blood-2003-09-3126","volume":"103","author":"KJ Peltola","year":"2004","unstructured":"Peltola, K. J. et al. Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3. Blood 103, 3744\u20133750 (2004).","journal-title":"Blood"},{"key":"1248_CR31","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.4049\/jimmunol.164.5.2533","volume":"164","author":"JD Lord","year":"2000","unstructured":"Lord, J. D. et al. The IL-2 receptor promotes lymphocyte proliferation and induction of the c-myc, bcl-2, and bcl-x genes through the trans-activation domain of Stat5. J. Immunol. 164, 2533\u20132541 (2000).","journal-title":"J. Immunol."},{"key":"1248_CR32","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1182\/blood.V89.9.3148","volume":"89","author":"A Matsumoto","year":"1997","unstructured":"Matsumoto, A. et al. CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 89, 3148\u20133154 (1997).","journal-title":"Blood"},{"key":"1248_CR33","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/j.ajpath.2011.01.020","volume":"178","author":"G Hoermann","year":"2011","unstructured":"Hoermann, G. et al. Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis. Am. J. Pathol. 178, 2344\u20132356 (2011).","journal-title":"Am. J. Pathol."},{"key":"1248_CR34","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1182\/bloodadvances.2018021063","volume":"2","author":"D Ribeiro","year":"2018","unstructured":"Ribeiro, D. et al. STAT5 is essential for IL-7-mediated viability, growth, and proliferation of T-cell acute lymphoblastic leukemia cells. Blood Adv. 2, 2199\u20132213 (2018).","journal-title":"Blood Adv."},{"key":"1248_CR35","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quintas-Cardama","year":"2010","unstructured":"Quintas-Cardama, A. et al. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 115, 3109\u20133117 (2010).","journal-title":"Blood"},{"key":"1248_CR36","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.bmc.2006.10.015","volume":"15","author":"S Nagashima","year":"2007","unstructured":"Nagashima, S. et al. Synthesis and evaluation of 2-{[2-(4-hydroxyphenyl)-ethyl]amino}pyrimidine-5-carboxamide derivatives as novel STAT6 inhibitors. Bioorg. Med. Chem. 15, 1044\u20131055 (2007).","journal-title":"Bioorg. Med. Chem."},{"key":"1248_CR37","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nchembio.1858","volume":"11","author":"DP Bondeson","year":"2015","unstructured":"Bondeson, D. P. et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat. Chem. Biol. 11, 611\u2013617 (2015).","journal-title":"Nat. Chem. Biol."},{"key":"1248_CR38","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.chembiol.2017.09.010","volume":"25","author":"DP Bondeson","year":"2018","unstructured":"Bondeson, D. P. et al. Lessons in PROTAC design from selective degradation with a promiscuous warhead. Cell Chem. Biol. 25, 78\u201387 (2018).","journal-title":"Cell Chem. Biol."},{"key":"1248_CR39","unstructured":"MOE 2020.09 (Chemical Computing Group ULC, 2020)."},{"key":"1248_CR40","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s10822-015-9835-6","volume":"29","author":"E Gianti","year":"2015","unstructured":"Gianti, E. & Zauhar, R. J. An SH2 domain model of STAT5 in complex with phospho-peptides define \u2018STAT5 Binding Signatures\u2019. J. Comput. Aided Mol. Des. 29, 451\u2013470 (2015).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"1248_CR41","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","volume":"276","author":"Z Otwinowski","year":"1997","unstructured":"Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307\u2013326 (1997).","journal-title":"Methods Enzymol."},{"key":"1248_CR42","doi-asserted-by":"crossref","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658\u2013674 (2007).","DOI":"10.1107\/S0021889807021206"},{"key":"1248_CR43","doi-asserted-by":"crossref","unstructured":"Emsley, P. et al. Features and development of Coot. Acta Crystallogr. D 66, 486\u2013501 (2010).","DOI":"10.1107\/S0907444910007493"},{"key":"1248_CR44","unstructured":"Bricogne, G. et al. BUSTER. Global Phasing Ltd.: Cambridge, United Kingdom (2017)."},{"key":"1248_CR45","unstructured":"Smart, O. S. et al. GRADE. Global Phasing Ltd.: Cambridge, United Kingdom (2017)."},{"key":"1248_CR46","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ab.2004.05.055","volume":"332","author":"Z Nikolovska-Coleska","year":"2004","unstructured":"Nikolovska-Coleska, Z. et al. Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. Anal. Biochem. 332, 261\u2013273 (2004).","journal-title":"Anal. Biochem."},{"key":"1248_CR47","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14806\/ej.17.1.200","volume":"17","author":"M Martin","year":"2011","unstructured":"Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet. J. 17, 10\u201312 (2011).","journal-title":"EMBnet. J."},{"key":"1248_CR48","unstructured":"Andrews, S. FastQC: a quality control tool for high throughput sequence data. Babraham Bioinformatics, Babraham Institute. https:\/\/www.bioinformatics.babraham.ac.uk\/projects\/fastqc\/"},{"key":"1248_CR49","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.12688\/f1000research.15931.1","volume":"7","author":"SW Wingett","year":"2018","unstructured":"Wingett, S. W. & Andrews, S. FastQ Screen: a tool for multi-genome mapping and quality control. F1000Res. 7, 1338 (2018).","journal-title":"F1000Res."},{"key":"1248_CR50","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"1248_CR51","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/1471-2105-12-323","volume":"12","author":"B Li","year":"2011","unstructured":"Li, B. & Dewey, C. N. RSEM: accurate transcript quantification from RNA-seq data with or without a reference genome. BMC Bioinformatics 12, 323 (2011).","journal-title":"BMC Bioinformatics"},{"key":"1248_CR52","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/ng0506-500","volume":"38","author":"M Reich","year":"2006","unstructured":"Reich, M. et al. GenePattern 2.0. Nat. Genet. 38, 500\u2013501 (2006).","journal-title":"Nat. Genet."},{"key":"1248_CR53","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1248_CR54","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","volume":"27","author":"A Liberzon","year":"2011","unstructured":"Liberzon, A. et al. Molecular Signatures Database (MSigDB) 3.0. Bioinformatics 27, 1739\u20131740 (2011).","journal-title":"Bioinformatics"},{"key":"1248_CR55","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"1248_CR56","doi-asserted-by":"publisher","first-page":"7150","DOI":"10.1021\/ac502040v","volume":"86","author":"GC McAlister","year":"2014","unstructured":"McAlister, G. C. et al. MultiNotch MS3 enables accurate, sensitive, and multiplexed detection of differential expression across cancer cell line proteomes. Anal. Chem. 86, 7150\u20137158 (2014).","journal-title":"Anal. Chem."},{"key":"1248_CR57","doi-asserted-by":"publisher","first-page":"D543","DOI":"10.1093\/nar\/gkab1038","volume":"50","author":"Y Perez-Riverol","year":"2022","unstructured":"Perez-Riverol, Y. et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 50, D543\u2013D552 (2022).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Chemical Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41589-022-01248-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41589-022-01248-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41589-022-01248-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T13:05:06Z","timestamp":1685451906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41589-022-01248-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1248"],"URL":"https:\/\/doi.org\/10.1038\/s41589-022-01248-4","relation":{},"ISSN":["1552-4450","1552-4469"],"issn-type":[{"value":"1552-4450","type":"print"},{"value":"1552-4469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,2]]},"assertion":[{"value":"23 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The University of Michigan has filed patent applications on inhibitors and degraders described in this study, which have been licensed to Oncopia Therapeutics, Proteovant Therapeutics and Roivant Sciences. S.W., A.K., L.B. M.W., D.M. and J.S. are co-inventors on one or more of these patent applications and receive royalties from the University of Michigan. The University of Michigan has received a research contract from Oncopia\/Proteovant\/Roivant, for which S.W. serves as the principal investigator. S.W. is a paid consultant to Proteovant\/Roivant and owns equity in Roivant. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}